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Abstract
Mitochondria form close physical contacts with a specialized domain of the endoplasmic reticulum (ER), known as
the mitochondria-associated membrane (MAM). This association constitutes a key signaling hub to regulate several
fundamental cellular processes. Alterations in ER–mitochondria signaling have pleiotropic effects on a variety of
intracellular events resulting in mitochondrial damage, Ca2+ dyshomeostasis, ER stress and defects in lipid
metabolism and autophagy. Intriguingly, many of these cellular processes are perturbed in neurodegenerative
diseases. Furthermore, increasing evidence highlights that ER–mitochondria signaling contributes to these diseases,
including Parkinson’s disease (PD). PD is the second most common neurodegenerative disorder, for which effective
mechanism-based treatments remain elusive. Several PD-related proteins localize at mitochondria or MAM and have
been shown to participate in ER–mitochondria signaling regulation. Likewise, PD-related mutations have been
shown to damage this signaling. Could ER–mitochondria associations be the link between pathogenic mechanisms
involved in PD, providing a common mechanism? Would this provide a pharmacological target for treating this
devastating disease?
In this review, we aim to summarize the current knowledge of ER–mitochondria signaling and the recent evidence
concerning damage to this signaling in PD.
Facts
● Endoplasmic reticulum (ER) and mitochondria form
close associations that constitute key signaling hubs
to regulate many cellular processes.
● ER–mitochondria contacts regulate many different
pathways, which are damaged in Parkinson’s disease
(PD).
● ER–mitochondria associations are altered in PD.
Open questions
● Are ER–mitochondria associations disrupted or
upregulated upon PD-related insults?
● Is ER–mitochondria signaling damage the common
link among the different pathways involved in PD?
● What are the molecular mechanisms implicated in
PD-related protein damage to ER–mitochondria
associations?
● Do other PD-related proteins alter ER–mitochondria
signaling?
● Is ER–mitochondria signaling also damaged in
sporadic PD?
● Can ER–mitochondria signaling be targeted
therapeutically?
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Parkinson’s disease (PD) is the most common move-
ment disorder and the second most common neurode-
generative disease after Alzheimer’s disease (AD). PD
patients typically experience difficulties with slowness of
movements (bradykinesia), involuntary shaking (tremor),
increased resistance to passive movement (rigidity) and
postural instability. The cardinal motor symptoms of PD
are attributable to the progressive degeneration of dopa-
minergic neurons in the pars compacta of the substantia
nigra (SNpc DA). PD is also characterized by the presence
of intraneuronal proteinaceous inclusions called Lewy
bodies (LB) and abnormal dystrophic neuronal processes
termed Lewy neurites in the surviving neurons1.
Although most cases are sporadic, mutations in several
genes, the PARK loci, have been unequivocally shown to
cause familial parkinsonism in 5–10% of cases. Impor-
tantly, the phenotypes of both the sporadic and familial
forms are essentially indistinguishable, implying that they
might share common underlying mechanisms. Mutations
in three genes, SNCA (best known as α-synuclein), LRRK2
(Leucine-rich repeat kinase 2), and VPS35 (Vacuolar
protein sorting-associated protein 35), are known to cause
a dominant form of PD, whereas mutations in PARK2
(parkin RBR E3 ubiquitin protein ligase, best known as
Parkin), PINK1 (PTEN-induced putative kinase 1), and
PARK7 (Parkinsonism associated deglycase, best known
as DJ-1) cause recessive-inherited forms of the disease2.
The discovery of such monogenic forms during the last
two decades has significantly advanced our understanding
of the pathogenic mechanisms involved in PD, as it allows
for the generation of animal and cellular models carrying
the mutant gene. Thus, although the precise mechanisms
underlying neuronal death in PD remain to be deter-
mined, damage to a plethora of cellular processes has
been widely reported. These include alterations in Ca2+
homeostasis, cellular proteostasis, axonal transport,
mitochondrial function, and neuroinflammation3. Con-
sequently, one of the difficulties in deciphering PD-related
toxicity consists of linking these apparently diverse
pathological changes to a common disease pathway.
Recently, several indications have argued in favor of
the possibility that perturbations in the
ER–mitochondrial network have an important role in the
pathogenesis of PD4,5. Indeed, ER–mitochondria com-
munication has been demonstrated to be altered in
several neurodegenerative diseases, including PD4. This
review is mainly devoted to discussing the evidence that
ER–mitochondria signaling dysfunction may have a role
in PD pathogenesis.
Endoplasmic reticulum–mitochondria associations
In the eukaryotic cell, communication and cooperation
between the different membrane-bound organelles must
take place to integrate cellular physiology. This integra-
tion depends upon effective crosstalk and one way in
which this is achieved is through direct membrane
contact. Thus, proper endoplasmic reticulum
(ER)–mitochondria communication requires the forma-
tion of specialized membrane microdomains at the con-
tact sites, defining short distances between membranes to
connect them6. The ER and mitochondria association is
the most studied and the first described inter-organelle
contact7. The ER is closely opposed to 5–20% of the
mitochondrial surface. The ER domain specialized in this
association is known as mitochondria-associated mem-
branes (MAMs) and can be smooth or ribosome-
containing rough ER membranes8,9.
ER–mitochondria tethering complexes
The presence of structures that appear to tether the two
organelles has been observed by electron microscopy in
many different cell types4,6,10–13 (Fig. 1). Early studies
revealed the proteinaceous nature of the tethers between
the two membranes6,14. Studies in yeast revealed the
presence of a protein complex, known as ERMES
(ER–mitochondria encounter structure)15. However, no
mammalian orthologues of ERMES proteins have been
identified yet; on the contrary, several different protein
complexes have been proposed as ER–mitochondria
tethers16. One of these complexes is based on the
interaction between the ER Ca2+ channel IP3R (inositol
1,4,5-trisphosphate receptor) and the OMM VDAC1
(voltage-dependent anion channel 1), that is the major
mitochondrial Ca2+ transport channel, in a ternary
binding complex with the mitochondrial chaperone
GRP75 (glucose-regulated protein 75)17. The ER sorting
molecule PACS-2 (phosphofurin acidic cluster sorting
protein-2) has also been shown to be involved in
ER–mitochondria associations18. Similarly, the interaction
between the ER protein Bap31 (B-cell receptor associated
protein 31) and the mitochondrial fission protein Fis1 has
been shown to bridge the mitochondria and the ER and
promote apoptosis19.
Another MAM protein, mitofusin 2 (MFN2), has also
been proposed as a tethering complex by establishing
homo- and heterotypic interactions with mitochondrial
MFN1/220. However, the role of MFN2 as an
ER–mitochondria tether has been challenged as several
recent studies from different laboratories have now shown
that loss of MFN2 leads to an increase and not a decrease
in ER–mitochondria contacts21–24. Thus, whether MFN2
is functionally involved in ER–mitochondria tethering
remains to be resolved.
The vesicle-associated membrane proteins-associated
proteins (VAPs) are integral ER membrane proteins,
which interact with a plethora of proteins to mediate
associations between the ER and other membranes25.
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These include mitochondria but also peroxisomes, the
Golgi, the plasma membrane, and the endo-lysosome
compartment26–30. Mammals have two homologous VAP
proteins, VAPA and VAPB, which share 76% similar or
identical amino acid residues31. VAPB binds to the
OMM protein, PTPIP51 (protein tyrosine phosphatase-
interacting protein 51) to tether ER with mitochon-
dria10,32. Thus, manipulating VAPB or PTPIP51 expres-
sion has been shown to induce appropriate changes in
ER–mitochondria contacts10,33. An amyotrophic lateral
sclerosis (ALS)-related VAPB mutation has been shown
to increase the PTPIP51-dependent interaction between
the ER and mitochondria32. Regarding PD, a recent study
showed that the PD-related protein α-synuclein interacts
with VAPB, decreasing the VAPB-PTPIP51 interaction
(see below)34.
In addition, PTPIP51 can interact with the oxysterol-
binding protein-related proteins ORP5 and ORP8 to tether
mitochondria to ER13. ORP proteins have been thought to
have a role as sterol sensor or transport proteins35,36.
Recently, PTPIP51 has been involved in regulating the
interaction of mitochondria with the sarcoplasmic reticu-
lum, a specialized type of ER, in cardiac function37.
Although rough ER–mitochondria contacts have long
been observed by electron microscopy6,38–40, the above
mentioned tethers appear to be specific for ribosome-
excluded mitochondria-smooth ER contacts. Interest-
ingly, a recent study has identified novel protein candi-
dates that reside at rough ER–mitochondria contact sites,
the OMM protein SYNJ2BP (synaptojanin 2 binding
protein), which interacts with the ER protein RRBP1
(ribosome- binding protein 1)41.
Cellular functions regulated by ER–mitochondria signaling
ER–mitochondria contacts are historically linked to
lipid metabolism and Ca2+ signaling8,9. Nevertheless,
further studies have revealed additional roles for
ER–mitochondria signaling in a variety of processes ran-
ging from intracellular trafficking of mitochondria and ER
to cell survival, energy metabolism, protein folding and
autophagy11,33,42–46. Here, we will give a brief description
of the most important ER–mitochondria signaling func-
tions (Fig. 2).
ER–mitochondria contacts serve as a platform for lipid
biosynthesis
ER–mitochondria contacts mediate shuttling of lipids
between the two organelles, which is necessary for the
synthesis of certain lipids such as phosphatidylcholine
(PC)47. In fact, this role in the transfer of phospholipids
Fig. 1 Endoplasmic reticulum–mitochondria tethering complexes. Multiple structures that tether mitochondria with the mitochondria-
associated membranes (MAMs) of endoplasmic reticulum (ER) have been described. Inositol 1,4,5-trisphosphate receptor (IP3R) and voltage-
dependent anion channel (VDAC1) interact via GRP75. Synaptojanin 2 binding protein (SYNJ2BP) interacts with the ribosome-binding protein 1
(RRBP1). The outer mitochondrial protein tyrosine phosphatase-interacting protein 51 (PTPIP51) interacts with vesicle-associated membrane proteins-
associated protein B (VAPB) or oxysterol-binding protein-related proteins (ORP5/8) at the ER. B-cell receptor associated protein 31 (BAP31) binds to
mitochondrial fission 1 protein (Fis1). ER-located mitofusin 2 (MFN2) interacts with mitochondrial MFN1/MFN2. Other proteins, such the ER sorting
molecule phosphofurin acidic cluster sorting protein-2 (PACS-2), have been involved in ER–mitochondria association integrity. Yeasts specific proteins
have also been described: the ER–mitochondria encounter structure (ERMES) complex, composed of four proteins: the outer mitochondrial
membrane proteins Mdm10 and Mdm34, the ER protein Mmm1, and the cytosolic protein Mdm12
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was the first function attributed to ER–mitochondria
associations9. For this, phosphatidylserine (PS) is first
synthesized in the MAM by the PS synthase 1 and 2;
then it is transferred to mitochondria where a dec-
arboxylase (PSD) converts it to phosphatidylethanola-
mine (PE); PE is crucial for the maintenance of
mitochondrial tubular morphology and therefore for
mitochondrial functions48,49. PE can be transferred
back to the ER, where phosphatidylethanolamine N-
methyltransferase-2 (PEMT2) converts it into PC47.
Inflammasome formation
Inflammation is a tightly regulated response of the
innate immune system to combat infection or tissue
injury and it involves the production of pro-inflammatory
cytokines. One of the innate immunity sensors that can
Fig. 2 Endoplasmic reticulum–mitochondria signaling function. The interaction between mitochondria and the MAMs of ER has been linked
with different cellular functions, including inflammasome formation; calcium (Ca2+) signaling, mitochondrial and ER dynamics, autophagy and lipid
biosynthesis. AMPK AMP-activated protein kinase, Casp-1 caspase-1, DRP1 dynamin-related protein 1, GRP75 glucose-regulated protein 75, IMM inner
mitochondrial membrane, IP3R inositol 145-trisphosphate receptor, MCU mitochondrial calcium uniporter, MFN2 mitofusin 2, NLRP3 NLR family pyrin
domain-containing 3, OMM outer mitochondrial membrane, PACS-2 phosphofurin acidic cluster sorting protein-2, PC phosphatidylcholine, PE
phosphatidylethanolamine, PEMT2 phosphatidylethanolamine N-methyltransferase 2, PS phosphatidylserine, PSD phosphatidylserine decarboxylases,
PTPIP51 protein tyrosine phosphatase-interacting protein 51, ROS radical oxygen species, TCA tricarboxylic acid cycle, UPR unfolded protein response,
VAPB vesicle-associated membrane proteins-associated protein B, VDAC1 voltage-dependent anion channel 1
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orchestrate inflammatory response, by secreting pro-
inflammatory cytokines IL-1β and IL-18, are cytosolic
multiprotein complexes termed inflammasomes. Upon its
activation, the inflammasome complex mediates activa-
tion of caspase-1, which represents a crucial step in the
secretion of the previously mentioned cytokines and
consequently drives the inflammatory response. The
NLRP3 inflammasome is the most studied inflammasome
and it is formed after the oligomerization of NLRP3 and
subsequent recruitment of apoptosis-associated Speck-
like protein with a caspase-recruitment domain and pro-
caspase-150. One class of these is the NOD-like receptors
(NLRs), which sense abnormal cytosolic changes. Upon
activation by ROS, some NLRs, including NLRP3, form
multiprotein complexes, which redistribute to MAM to
activate the inflammasome51.
ER–mitochondria contact sites are crucial for efficient cellular
Ca2+ handling and Ca2+-regulated processes
Early studies by Rizzuto and co-workers showed that
ER–mitochondria associations mediate Ca2+ transfer
from ER to mitochondria8,17,52. These studies demon-
strated that the close apposition between the two orga-
nelles at contact sites allows the formation of hotspots
that meet the low affinity threshold of mitochondrial Ca2+
uptake mechanisms. Consequently, MAM are enriched in
proteins associated with Ca2+ handling such as channels
and chaperones53. As previously mentioned, the ER Ca2+
channel IP3R contacts VDAC1 through the molecular
chaperone GRP75, mediating the Ca2+ transfer from the
ER to mitochondria17. In addition, chaperones located at
MAM, like calnexin and calreticulin, can interact with the
IP3R and the ER Ca2+ transport ATPase SERCA2b to
regulate Ca2+ signaling53. Although the ER is the major
Ca2+ store, mitochondria are also an important Ca2+
reserve, especially in neurons, so the Ca2+ transfer
between them is crucial for the maintenance of cellular
Ca2+ homeostasis54.
One of the first roles assigned to the mitochondrial Ca2+
uptake from the ER was the regulation of mitochondrial
oxidative metabolism55. Mitochondrial activities are driven
in a Ca2+-dependent manner as three dehydrogenases in
the tricarboxylic acid cycle (pyruvate-, α-ketoglutarate-,
and isocitrate-dehydrogenases) as well as mitochondrial
FAD-glycerol phosphate dehydrogenase are activated by
Ca2+55. However, prolonged mitochondrial Ca2+ overload
compromises mitochondrial function by causing a tran-
sient collapse of the mitochondrial membrane potential,
leading to necrosis or apoptosis54,56.
Regarding their role in Ca2+ homeostasis and bioener-
getics57–59, ER–mitochondria associations has been
demonstrated to regulate macroautophagy33. Macro-
autophagy, (hereafter called autophagy), is a lysosomal
mechanism of degradation that can be activated during
metabolic energy stress, a condition in which the process
promotes the recycling of intracellular contents to pro-
duce metabolic intermediates60. As mentioned above,
mitochondrial Ca2+ uptake through ER–mitochondria
contact sites is necessary for ATP production. Conse-
quently, blocking Ca2+ transfer to mitochondria was
shown to stimulate autophagy as a physiological response
of the cell to the altered bioenergetics57. Recently the
ER–mitochondria tethering complex VAPB-PTPIP51 was
shown to modulate autophagy, involveing their role in
mediating IP3R-mediated delivery of Ca2+ from ER stores
to mitochondria33.
Furthermore, ER–mitochondria contacts serve as
membrane source for autophagosome formation44. Dur-
ing the autophagy process, specialized double-membrane
vesicles, known as autophagosomes, are formed. Autop-
hagosome formation starts with an initial isolation
membrane, known as the phagophore, which expands by
de novo membrane synthesis and recruitment of lipids
and proteins from different membrane sources. Then, the
autophagosome engulfs this material for degradation and
fuses with the endosomal–lysosomal system where the
cargo is degraded and recycled60. Several organelles have
been proposed to provide the nucleation site and to
contribute to the formation and expansion of the autop-
hagosomal membrane. The involvement of ER and
mitochondria to this process has been extensively repor-
ted, including the ER–mitochondria contact sites61.
Hence, upon autophagy induction, several pro-autophagic
proteins relocalize to MAMs to initiate autophagosome
formation44,62–64.
Regulation of ER and mitochondrial dynamics and
homeostasis
ER–mitochondria associations are also important in
the movement of both organelles. ER and mitochondria
are dynamic organelles transported on cytoskeletal
elements. Importantly, ER–mitochondria contacts have
been shown to be maintained while both organelles are
moving42. This transport involves specialized molecular
machinery, as molecular motors such as dynein and
kinesin, which are tightly regulated by Ca2+ sensors65–67.
Hence, a rise in cytosolic Ca2+ concentration has been
shown to produce an arrest of the movements of both
organelles68–70.
Besides participation in mitochondrial motility, MAMs
also participate in the regulation of mitochondrial mor-
phology and biogenesis, which is maintained by the bal-
ance between fission and fusion events71. Accordingly,
MAM is also enriched in proteins related to the control of
mitochondrial fission11 and dynamics72. Indeed, mito-
chondrial fission occurs at positions where ER tubules
contact and constrict mitochondria11. These constrictions
facilitate the recruitment of DRP1 (dynamin-related
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protein), a major player in mitochondrial fission73. In
addition, ER–mitochondria contacts have a key role dur-
ing mitophagy, the selective degradation of mitochondria
through the autophagy pathway74. During hypoxia, the
interaction between the OMM protein FUNDC1 and the
ER chaperone calnexin gets disrupted and, as mitophagy
proceeds, FUNDC1 preferably recruits DNM1L/DRP1 to
drive mitochondrial fission promoting mitophagy64.
Importantly, a recent study showed the recruitment into
MAM of the PD-related proteins PINK1 and Parkin with
downstream effects on ER–mitochondria associations and
mitophagy, as explained in detail later in this review62.
The homeostasis of the ER can be altered by several
conditions including Ca2+ depletion from its lumen and
oxidative stress. These perturbations result in disruption
of the folding process in the ER, leading to the accumu-
lation of misfolded/unfolded proteins and ER stress. ER
stress then activates the unfolded protein response (UPR),
a complex signal-transduction pathway that mediates
cellular adaptation to restore ER homeostasis75. A num-
ber of ER protein folding chaperones are present in MAM
and alterations to ER–mitochondria signaling is linked to
UPR53 For example, the structural uncoupling of ER from
mitochondria by depletion of PACS-2 or MFN2 was
shown to induce ER stress and the UPR18,76,77. Likewise,
VAPB also has roles in the UPR78,79.
In consequence, disease-related insults that cause an
abnormal tightening or loosening of ER–mitochondria
contacts are predicted to be detrimental to cells. There-
fore, it is not surprising that alterations in the
ER–mitochondria associations have been described in
several diseases, including a number of neurodegenerative
diseases4,80–82.
ER–mitochondria signaling in neurodegeneration
Neurodegenerative diseases including PD, AD, and
ALS/FTD (frontotemporal dementia) share several
obvious features: they are characterized by progressive
nervous system dysfunction, affect millions of people
worldwide and there is still no cure for any of them.
Furthermore, despite affecting different brain regions
PD, AD, and ALS/FTD also share other characteristics
suggesting that common cellular processes may
converge4.
Thus, whilst the precise mechanisms remain to be
determined, a variety of cellular processes are damaged in
all of them, including Ca2+ dysregulation, defects in
axonal transport, neuroinflammation, loss of cellular
proteostasis and mitochondrial dysfunction83–88 (Fig. 3).
Remarkably, ER–mitochondria associations, regulates all
of those processes. The findings that alterations in
ER–mitochondria associations occur in neurodegenera-
tive diseases have given rise to the hypothesis that
damaged ER–mitochondria signaling is a common
potential therapeutic target amongst distinct age-
dependent neurodegenerative disorders.
Fig. 3 Proposed model for endoplasmic reticulum–mitochondria signaling in PD. ER–mitochondrial axis appears to be essential for the healthy
neurons. Conversely, the disruption of this interaction may involve the develop of some processes as: mitochondrial dysfunction, induction of
oxidative stress, calcium (Ca2+) dyshomeostasis, autophagy defects or neuroinflammation, which induce neuronal damage and trigger
neurodegenerative diseases as PD
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This review focuses on current knowledge of
ER–mitochondria signaling in PD. The roles for MAM in
other neurodegenerative diseases will be addressed in
other chapters of this special issue and have also been
recently reviewed in ref.4.
PD and ER–mitochondria signaling
What causes SNpc DA neurons to die in PD?
This is one of the major unresolved questions that has
puzzled researchers for many years. Although the
mechanisms responsible for the preferential loss of SNpc
DA neurons in PD are still a debate, several studies show
evidence for a role of Ca2+ signaling in PD pathogen-
esis89,90. Surmeier et al.91 proposed that the selective
vulnerability of SNpc DA neurons relies on their unusual
physiological characteristic; adult SNpc DA neurons are
autonomously active, this means that they generate action
potentials in the absence of conventional synaptic input92.
This activity is sustained by their specific voltage-
dependent L-type Ca2+ channels, the Cav1.3 channels,
which allow Ca2+ influx that contributes to the mem-
brane potential threshold underlying autonomous pace-
making, causing sustained increases in cytosolic Ca2+
concentrations in these cells93,94. As the spatiotemporal
pattern of Ca2+ signaling is crucial for the specificity of
cellular responses, Ca2+ must be under a tight homeo-
static control which requires energy. Consequently, SNpc
DA neurons experience a high ATP demand that com-
promises mitochondrial function and increases the pro-
duction of reactive oxygen species. These events would
have detrimental effects on neuronal viability and could
amplify the effects of environmental factors or genetic
defects89.
Likewise, both mitochondria and ER have been widely
linked to pathogenesis in PD95,96. Toxins that nominally
target mitochondria have been shown to induce dopamine
cell degeneration96. Furthermore, several studies have
evidenced a potential link between proteins known to
cause familial PD and defects in mitochondria96.
Apart from a Ca2+ store, the ER is crucial in cellular
proteostasis as it is responsible for the production,
delivery and degradation of proteins75. Loss of proteos-
tasis is part of the pathogenesis of many neurodegenera-
tive diseases, including PD97. As previously mentioned,
one of the hallmarks of PD is the formation of LBs, which
reflects a deficiency in proteostasis that is accompanied by
signs of ER stress98. As a mechanism for proteostasis,
autophagy has a crucial role in the maintenance of protein
and organelle homeostasis in the axons, especially in
SNpc neurons, which pose an enormous axonal field99. In
fact, many studies support a role for autophagy in PD100.
Given its essential role in the above mentioned cellular
processes, perturbations in ER–mitochondria associations
are expected to be especially detrimental to SNc DA
neurons. Several familial PD-related proteins have been
shown to cause alterations in ER–mitochondria signal-
ing34,62,101–106. However, there is not yet a consensus on
the effects of these different PD-associated insults, nor on
the mechanisms leading to altered ER–mitochondria
associations, which are still unclear. Likewise, whether the
disease begins with the dysfunction of ER–mitochondria
signaling remains elusive.
Despite the plausible role of ER–mitochondria signaling
in PD, ER–mitochondria contacts are poorly characterized
in neurons and the exact role of these associations in
neuronal (patho)physiology also remains unclear. Several
studies have confirmed the presence of ER–mitochondria
contacts in neurons107–110. The presence of these contacts
at synapses suggests a role in synaptic activity. In fact, in
mouse respiratory neurons, ER–mitochondria axis-
mediated Ca2+ handling was shown to determine exocy-
tosis and synaptic activity107. MAMs at synapses may have
a critical role in many aspects of mitochondrial biology,
which have a direct impact on synaptic activity. As pre-
viously mentioned, the accumulation of Ca2+ in the
mitochondria leads to the activation of oxidative phos-
phorylation and to ATP production which is crucial to
meet the metabolic demands associated with neuronal
activity111. However, the sustained mitochondrial Ca2+
overload driven by the pacemaking activity in SNpc
dopaminergic neurons may ultimately compromise ATP
production93. Consequently, any types of alteration in
ER–mitochondria associations are expected to be poten-
tially damaging to neurons, especially SNpc DA neurons
(Fig. 4).
α-Synuclein
α-Synuclein has a central role in the pathogenesis of
PD112, however, the normal function of α-synuclein and
its precise role in PD remain poorly understood113.
α-Synuclein is a 140 amino acid, lipid-binding protein,
which is abundantly expressed in the human, brain and
predominantly localized in the presynaptic terminals of
neurons. Within neurons, α-synuclein localizes to cyto-
solic and membrane compartments including synaptic
vesicles, mitochondria, and the ER114,115. In this regard, its
membrane localization involves targeting to lipid rafts,
also known as detergent-resistant membranes, enriched in
cholesterol and acidic phospholipids116. Indeed, a sub-
population of α-synuclein is present in MAM34,103,117.
Several studies suggest that α-synuclein is involved in
modulating synaptic integrity and function118,119. In
addition, overexpression of wild-type or familial mutant
α-synuclein has been shown to damage a plethora of
physiological processes. These include Ca2+ home-
ostasis101,120, lipid metabolism103, the ER75, autophagy121,
and mitochondrial defects96. As mentioned previously, all
of these physiological processes are regulated by signaling
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between ER and mitochondria, so the effects of
α-synuclein on ER–mitochondria associations have been
investigated.
Until now, three different groups have reported that α-
synuclein perturbs ER–mitochondria associations34,101,103.
However, the nature of perturbation differs between these
studies.
Cali et al.101 reported a role for α-synuclein in mod-
ulating ER–mitochondria associations with downstream
effects in Ca2+ homeostasis in HeLa cells. Indeed, mea-
surement of Ca2+ exchange between the two organelles is a
recognized measurement of MAM activity4. They observed
that overexpression of wild-type α-synuclein increases,
while downregulation decreases, mitochondrial Ca2+
uptake. The quantification of the ER–mitochondria asso-
ciations also revealed an increase in the co-localization of
ER and mitochondrial markers in cells overexpressing
wild-type α-synuclein, suggesting that α-synuclein favors
ER–mitochondria contacts. Intriguingly, at high levels of α-
synuclein expression, induced by high doses of VPA or
TAT α-synuclein fusion protein, there was a drastic
reduction in mitochondrial Ca2+ uptake. The authors
observed that at those high levels of overexpression α-
synuclein re-localizes into cytoplasmic foci. This may
reduce the ability of α-synuclein to mediate
ER–mitochondria contacts, representing a loss of function.
Later, Guardia-Laguarta et al.103 showed that α-
synuclein localizes at MAM and that familial PD mutant
α-synuclein associates less than wild-type protein with
MAM. This correlates with a decrease in MAM function
in cells overexpressing mutant α-synuclein but not wild-
type. In this case, the physiological readout of
ER–mitochondria associations utilized was the conversion
of PS into PE. In these studies, the measurement of
ER–mitochondria apposition revealed a lower degree of
ER–mitochondria apposition in M17 cells overexpressing
familial PD mutant α-synuclein but also in HeLa cells
overexpressing the wild-type protein.
Both studies utilized confocal microscopy to analyze
ER–mitochondria apposition. However, ER–mitochondria
associations are defined by 10–30-nm distances,
significantly below of confocal microscopy resolution
(∼200 nm)6,16,122,123.
Recently, Paillusson et al.34 also addressed the role of α-
synuclein in ER–mitochondria contacts using high resolu-
tion techniques such as electron microscopy, structured
illumination microscopy, and proximity ligation assays.
Such methods afford better resolution for properly quan-
tifying ER–mitochondria associations. They reported that
overexpression of either wild-type or familial PD mutant α-
synuclein decreases ER–mitochondria contacts. Conse-
quently, these effects disrupt Ca2+ exchange between the
two organelles and mitochondrial ATP production. In
addition, this study showed that α-synuclein binds to the
tethering protein VAPB and decreases the VAPB-PTPIP51
interaction, which is proposed as the mechanism by which
Fig. 4 Modulators of ER–mitochondria associations. Several PD-associated proteins localize at the ER–mitochondrial (M) axis and have been
shown to participate in ER–mitochondria signaling regulation. Proteins such as α-synuclein (α-syn), DJ-1, PINK1 (PTEN-induced putative kinase 1), or
Parkin have an important role in the preservation of healthy cells by regulation of calcium (Ca2+) homeostasis and the autophagic responses under
different stimulus (a). Dysfunction of these PD-associated proteins leads to a non-efficient interaction between ER and mitochondria that triggers cell
damage (b). IP3R inositol 145-trisphosphate receptor, PTPIP51 protein tyrosine phosphatase-interacting protein 51, VAPB VAMP-associated protein B,
VDAC1 voltage-dependent anion channel 1
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it disrupts the contacts. Importantly, this disruption was
also seen in neurons derived from induced pluripotent
stem cells from familial PD patients harboring pathogenic
triplication of the α-synuclein gene34.
PINK1 and Parkin
Loss-of-function mutations in PINK1 or PARK2 genes
are associated with juvenile-onset autosomal recessive
forms of PD112. Parkin (PARK2 gene expression product)
is an ubiquitin E3 ligase that targets specific substrates for
degradation. In addition, Parkin has been demonstrated to
regulate mitochondrial biogenesis, bioenergetics, dynam-
ics, transport, and degradation124. PINK1 encodes a
mitochondrial protein kinase that also protects mito-
chondrial integrity at different levels. In addition, together
with Parkin, PINK1 controls the mechanism of mito-
phagy125. Therefore, upon conditions of mitochondrial
depolarization, PINK1 selectively accumulates on the
surface of damaged mitochondria, where it phosphor-
ylates and recruits both ubiquitin and Parkin. Parkin then
translocates from the cytosol to the OMM and there
ubiquitinates specific substrates (such as MFNs and
VDAC1), leading their proteasomal degradation126–128.
Next, these mitochondria are associated to the forming
autophagosome membranes by specific ubiquitin-binding
receptor proteins (e.g., p62 and optineurin) and after-
wards incorporated within autophagosomes129,130.
As previously mentioned, several pro-autophagic proteins
relocalize to MAMs to initiate autophagosome forma-
tion44,62–64. Similarly, contact regions between the ER and
impaired mitochondria have been shown to be prime loca-
tions for Parkin-mediated mitophagy and local recruitment
of autophagosome precursors131. Recently, Gelmetti et al.62
reported that PINK1 and Parkin are recruited to MAM
upon mitochondrial depolarization. PINK1 relocation into
MAM seems to be necessary for the recruitment of the
autophagy machinery to that area. Furthermore, Parkin
translocates into ER–mitochondria contact sites in condi-
tions of excitotoxicity in neurons. However in this case,
translocation is not associated with mitophagy and it might
be instead related with a distinct unknown pathway that
needs to be further investigated104.
Apart from the aforementioned role in mitophagy, sev-
eral studies have shown that PARKIN accumulates at both
mitochondria and ER–mitochondria associations and
modulates ER–mitochondrial crosstalk102,105. Once more,
the direction of the modulatory effects is controverted.
Cali et al.102 reported that Parkin overexpression
enhanced ER–mitochondria coupling and its functions.
On the contrary, siRNA loss of Parkin caused a decrease
in ER–mitochondria signaling associated with weaker
mitochondrial Ca2+ potentials and ATP production.
Conversely, Gautier et al.105 reported that
ER–mitochondria associations are instead increased in
primary fibroblasts from PARK2 knockout mice and PD
patients with PARK2 mutations. This observation corre-
lated with Ca2+ dyshomeostasis and increased levels of
MFN2105.
Once more, these controverted finding highlights the
difficulties involved in studies of contact sites between the
ER and mitochondria. Morphological changes of these
organelles, networks, and technical limitations such as the
resolution limits of confocal microscopy, may introduce bias
into these analyses. For example, the acute siRNA Parkin
depletion used for the first study-induced mitochondrial
fragmentation102, whereas this is not observed in fibroblasts
from PARK2 KO mice or from patients with PARK2
mutations105. Another difficulty with these different models
is the possibility of potential compensation mechanisms.
DJ-1
Diverse mutations, including deletions and point
mutations, in the DJ-1 gene, have been linked to auto-
somal recessive early-onset parkinsonism132. DJ-1 protein
has a role in the protection against oxidative stress and
mitochondria dynamics; however, the mechanism of its
protective function is still unknown. Thus, different
functions have been suggested for DJ-1, these include
characterization as a redox sensor and an antioxidant
scavenger, a chaperone with protease activity, or a tran-
scriptional regulator133. DJ-1 is localized in the cytosol
and the nucleus. During oxidative stress DJ-1 was shown
to translocate to the OMM to maintain a healthy mito-
chondrial environment133. However, Ottolini et al.106
showed that DJ-1 was localized at the MAMs but not in
the pure mitochondrial fraction. This study also showed
that DJ-1 overexpression augmented mitochondrial Ca2+
uptake, whereas reduced levels of DJ-1 caused
mitochondria fragmentation and decreased mitochondrial
Ca2+ uptake. By confocal microscopy studies, they also
observed an increased ER–mitochondria association when
overexpressing DJ-1. Moreover, its overexpression coun-
teracted p53-mediated effects on mitochondrial dereg-
ulation, suggesting that DJ-1 might contribute to maintain
ER–mitochondria tethering.
Conclusions and future
Although the exact pathological mechanisms under-
lying PD remain largely unclear a plethora of cellular
pathways are known to be damaged. The discovery that
ER–mitochondria signaling, which regulates many of
those pathways, are also damaged in PD has highlight the
possibility of a common link among them. Therefore,
ER–mitochondria signaling may represent a possible drug
target upstream of those pathways. However, more
research should be done before gaining a clearer under-
standing of the links between ER–mitochondria signaling and
the pathogenesis of PD. Hence, many questions remain
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unclear. Although the evidence discussed here supports the
hypothesis that deregulation of ER–mitochondria signaling
has an important role in PD pathogenesis, it is still unclear as
to whether ER–mitochondria associations are either upregu-
lated or disrupted upon PD-related insults. Combined, the
findings reviewed above highlight the complexity of studying
ER–mitochondria associations. Therefore, additional research
is needed to gain further insight into the mechanisms of
tethering of both organelles, especially in relation to neurons.
Furthermore, investigating whether other PD-related
proteins also alter the mitochondria–ER axis or if this is
altered in sporadic cases, would be useful to address a
possible general pathway for PD. Mutations in LRRK2 are
related to both familial and sporadic PD134. Autosomal-
dominant mutations in LRRK2 have been shown to cause
deficits in intracellular Ca2+ handling, mitochondrial
depolarization and increased mitophagy, which can be
prevented by L-type Ca2+ channel inhibitors135–137.
However, whether this is due to altered ER–mitochondria
communication remains to be determined.
Another pressing issue is how ER–mitochondria associations
can be targeted therapeutically. Likewise, a better under-
standing in how ER–mitochondria tethers are functionally
regulated is crucial to move drug development forward.
In conclusion, more studies are required to enhance our
understanding of PD mechanisms and its relation to
ER–mitochondria signaling.
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